دورية أكاديمية
أعرض في EDS

Prophylactic drug management for febrile seizures in children.

التفاصيل البيبلوغرافية
العنوان: Prophylactic drug management for febrile seizures in children.
المؤلفون: Offringa M; Child Health Evaluative Sciences, Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada, M5G 1X8., Newton R; Department of Paediatric Neurology, Royal Manchester Children's Hospital, Hospital Road, Pendlebury, Manchester, UK, M27 4HA., Cozijnsen MA; Pediatric Gastroenterology, Erasmus MC - Sophia Children's Hospital, 's-Gravendijkwal 230 3015 CE, Rotterdam, Netherlands, 3000 CB., Nevitt SJ; Department of Biostatistics, University of Liverpool, Block F, Waterhouse Building, 1-5 Brownlow Hill, Liverpool, UK, L69 3GL.
المصدر: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2017 Feb 22; Vol. 2. Cochrane AN: CD003031. Date of Electronic Publication: 2017 Feb 22.
نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE
أسماء مطبوعة: Publication: 2004- : Chichester, West Sussex, England : Wiley
Original Publication: Oxford, U.K. ; Vista, CA : Update Software,
مواضيع طبية MeSH: Anticonvulsants/*therapeutic use , Antipyretics/*therapeutic use , Seizures, Febrile/*prevention & control, Anticonvulsants/adverse effects ; Antipyretics/adverse effects ; Child ; Child, Preschool ; Humans ; Infant ; Randomized Controlled Trials as Topic ; Recurrence
مستخلص: Background: Febrile seizures occurring in a child older than one month during an episode of fever affect 2% to 4% of children in Great Britain and the United States and recur in 30%. Rapid-acting antiepileptics and antipyretics given during subsequent fever episodes have been used to avoid the adverse effects of continuous antiepileptic drugs.
Objectives: To evaluate primarily the effectiveness and safety of antiepileptic and antipyretic drugs used prophylactically to treat children with febrile seizures; but also to evaluate any other drug intervention where there was a sound biological rationale for its use.
Search Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2016, Issue 7); MEDLINE (1966 to July 2016); Embase (1966 to July 2016); Database of Abstracts of Reviews of Effectiveness (DARE) (July 2016). We imposed no language restrictions. We also contacted researchers in the field to identify continuing or unpublished studies.
Selection Criteria: Trials using randomised or quasi-randomised participant allocation that compared the use of antiepileptic, antipyretic or other plausible agents with each other, placebo or no treatment.
Data Collection and Analysis: Two review authors (RN and MO) independently applied predefined criteria to select trials for inclusion and extracted the predefined relevant data, recording methods for randomisation, blinding and exclusions. For the 2016 update a third author (MC) checked all original inclusions, data analyses, and updated the search. Outcomes assessed were seizure recurrence at 6, 12, 18, 24, 36, and 48 months and at age 5 to 6 years in the intervention and non-intervention groups, and adverse medication effects. We assessed the presence of publication bias using funnel plots.
Main Results: We included 40 articles describing 30 randomised trials with 4256 randomised participants. We analysed 13 interventions of continuous or intermittent prophylaxis and their control treatments. Methodological quality was moderate to poor in most studies. We found no significant benefit for intermittent phenobarbitone, phenytoin, valproate, pyridoxine, ibuprofen or zinc sulfate versus placebo or no treatment; nor for diclofenac versus placebo followed by ibuprofen, acetaminophen or placebo; nor for continuous phenobarbitone versus diazepam, intermittent rectal diazepam versus intermittent valproate, or oral diazepam versus clobazam.There was a significant reduction of recurrent febrile seizures with intermittent diazepam versus placebo or no treatment, with a risk ratio (RR) of  0.64 (95% confidence interval (CI) 0.48 to 0.85 at six months), RR of 0.69 (95% CI 0.56 to 0.84) at 12 months, RR 0.37 (95% CI 0.23 to 0.60) at 18 months, RR 0.73 (95% CI 0.56 to 0.95) at 24 months, RR 0.58 (95% CI 0.40 to 0.85) at 36 months, RR 0.36 (95% CI 0.15 to 0.89) at 48 months, with no benefit at 60 to 72 months. Phenobarbitone versus placebo or no treatment reduced seizures at 6, 12 and 24 months but not at 18 or 72 month follow-up (RR 0.59 (95% CI 0.42 to 0.83) at 6 months; RR 0.54 (95% CI 0.42 to 0.70) at 12 months; and RR 0.69 (95% CI 0.53 to 0.89) at 24 months). Intermittent clobazam compared to placebo at six months resulted in a RR of 0.36 (95% CI 0.20 to 0.64), an effect found against an extremely high (83.3%) recurrence rate in the controls, which is a result that needs replication.The recording of adverse effects was variable. Lower comprehension scores in phenobarbitone-treated children were found in two studies. In general, adverse effects were recorded in up to 30% of children in the phenobarbitone-treated group and in up to 36% in benzodiazepine-treated groups. We found evidence of publication bias in the meta-analyses of comparisons for phenobarbitone versus placebo (eight studies) at 12 months but not at six months (six studies); and valproate versus placebo (four studies) at 12 months, with too few studies to identify publication bias for the other comparisons.Most of the reviewed antiepileptic drug trials are of a methodological quality graded as low or very low. Methods of randomisation and allocation concealment often do not meet current standards; and treatment versus no treatment is more commonly seen than treatment versus placebo, leading to obvious risks of bias. Trials of antipyretics and zinc were of higher quality.
Authors' Conclusions: We found reduced recurrence rates for children with febrile seizures for intermittent diazepam and continuous phenobarbitone, with adverse effects in up to 30%. Apparent benefit for clobazam treatment in one trial needs to be replicated to be judged reliable. Given the benign nature of recurrent febrile seizures, and the high prevalence of adverse effects of these drugs, parents and families should be supported with adequate contact details of medical services and information on recurrence, first aid management and, most importantly, the benign nature of the phenomenon.
التعليقات: Update of: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003031. (PMID: 22513908)
Update in: Cochrane Database Syst Rev. 2021 Jun 16;6:CD003031. (PMID: 34131913)
References: Pediatrics. 1999 Jun;103(6):e86. (PMID: 10353983)
Clin Pediatr (Phila). 1999 Jul;38(7):387-94. (PMID: 10416094)
BMJ. 2000 Jul 8;321(7253):83-6. (PMID: 10884257)
J Pediatr. 2001 Apr;138(4):548-52. (PMID: 11295719)
Epilepsia. 2002 Jun;43(6):581-6. (PMID: 12060016)
Arch Neurol. 2002 Jul;59(7):1137-41. (PMID: 12117362)
Brain. 2002 Dec;125(Pt 12):2668-80. (PMID: 12429594)
Br Med J. 1976 Mar 6;1(6009):559-61. (PMID: 1260273)
Brain Dev. 2003 Aug;25(5):304-12. (PMID: 12850508)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
Eur J Paediatr Neurol. 2004;8(3):131-4. (PMID: 15120684)
Lancet Neurol. 2004 Jul;3(7):421-30. (PMID: 15207799)
Epilepsy Curr. 2003 Jul;3(4):115-118. (PMID: 15309049)
Indian J Pediatr. 2005 Jan;72(1):31-3. (PMID: 15684445)
Epilepsy Res. 2006 Aug;70 Suppl 1:S190-8. (PMID: 16887333)
Neurology. 2006 Aug 22;67(4):687-90. (PMID: 16924025)
J Child Neurol. 2006 Dec;21(12):1036-40. (PMID: 17156694)
BMJ. 1991 Nov 30;303(6814):1373-6. (PMID: 1760604)
Acta Neurol Scand Suppl. 1991;135:1-24. (PMID: 1858481)
Arch Pediatr Adolesc Med. 2009 Sep;163(9):799-804. (PMID: 19736332)
Epilepsia. 2010 Apr;51(4):676-85. (PMID: 20196795)
Paediatr Perinat Epidemiol. 1991 Apr;5(2):181-8. (PMID: 2052480)
Indian J Pediatr. 2011 Jan;78(1):38-40. (PMID: 20890683)
J Pediatr. 1990 Mar;116(3):329-37. (PMID: 2137875)
J Pediatr. 1990 Sep;117(3):490-4. (PMID: 2202804)
Acta Neurol Scand. 1990 Jul;82(1):17-20. (PMID: 2239131)
N Engl J Med. 1990 Feb 8;322(6):364-9. (PMID: 2242106)
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003031. (PMID: 22513908)
Iran Red Crescent Med J. 2011 Jun;13(6):438-9. (PMID: 22737510)
Brain. 2013 Oct;136(Pt 10):3140-50. (PMID: 24014518)
Gene. 2014 Jan 1;533(1):26-31. (PMID: 24076350)
Dev Med Child Neurol. 1989 Oct;31(5):617-25. (PMID: 2509264)
Nutrition. 2015 Nov-Dec;31(11-12):1358-61. (PMID: 26429655)
Iran J Child Neurol. 2016 Winter;10(1):21-4. (PMID: 27057183)
Pediatrics. 1987 Aug;80(2):165-74. (PMID: 3112727)
An Esp Pediatr. 1987 Nov;27(5):379-81. (PMID: 3125773)
Epilepsia. 1988 Nov-Dec;29(6):794-804. (PMID: 3142761)
Arch Dis Child. 1988 Oct;63(10):1189-91. (PMID: 3143313)
Acta Neurol Scand. 1988 Nov;78(5):414-7. (PMID: 3218448)
Acta Neurol (Napoli). 1977 Nov-Dec;32(6):884-91. (PMID: 343515)
Indian J Pediatr. 1986 May-Jun;53(3):397-400. (PMID: 3531001)
Arch Dis Child. 1978 Aug;53(8):660-3. (PMID: 361000)
Clin Pediatr (Phila). 1979 Jul;18(7):426-30. (PMID: 378504)
J Pediatr. 1979 Sep;95(3):361-5. (PMID: 381616)
Arch Dis Child. 1985 Nov;60(11):1045-9. (PMID: 3907504)
J Pediatr. 1985 Mar;106(3):487-90. (PMID: 3973786)
Clin Pediatr (Phila). 1970 May;9(5):283-6. (PMID: 5445067)
Lancet. 1981 Sep 19;2(8247):600-4. (PMID: 6116084)
Boll Soc Ital Biol Sper. 1980 Jun 15;56(11):1187-91. (PMID: 6255970)
Am J Dis Child. 1983 Sep;137(9):892-5. (PMID: 6351594)
Neuropediatrics. 1984 Feb;15(1):37-42. (PMID: 6424041)
Epilepsia. 1984;25 Suppl 1:S32-9. (PMID: 6425044)
An Esp Pediatr. 1984 May;20(8):763-9. (PMID: 6476623)
Pediatrics. 1978 May;61(5):728-31. (PMID: 662511)
Arch Dis Child. 1980 Mar;55(3):171-4. (PMID: 6770760)
Brain Dev. 1981;3(4):385-93. (PMID: 6797314)
Pediatrie. 1982 Sep;37(6):433-45. (PMID: 6818516)
Clin Pediatr (Phila). 1981 Mar;20(3):208-11. (PMID: 7009019)
Arch Dis Child. 1981 Nov;56(11):836-40. (PMID: 7305427)
Pediatrics. 1981 Dec;68(6):820-3. (PMID: 7322717)
J Pediatr. 1980 Jul;97(1):16-21. (PMID: 7381637)
Arch Pediatr Adolesc Med. 1995 Jun;149(6):632-7. (PMID: 7767417)
J Pediatr. 1995 Jun;126(6):991-5. (PMID: 7776115)
J Pediatr. 1994 Apr;124(4):574-84. (PMID: 8151472)
Epilepsia. 1994;35 Suppl 2:S1-6. (PMID: 8275976)
Indian Pediatr. 1993 May;30(5):637-42. (PMID: 8282390)
Epilepsia. 1993 Jul-Aug;34(4):592-6. (PMID: 8330566)
Pediatrics. 1977 Mar;59(3):378-85. (PMID: 840556)
Pediatr Neurol. 1993 Mar-Apr;9(2):94-100. (PMID: 8499051)
N Engl J Med. 1993 Jul 8;329(2):79-84. (PMID: 8510706)
Epilepsia. 1996 Feb;37(2):126-33. (PMID: 8635422)
Arch Dis Child. 1996 Jan;74(1):13-8. (PMID: 8660037)
No To Hattatsu. 1997 Jul;29(4):278-84. (PMID: 9248286)
Hum Mol Genet. 1998 Jan;7(1):63-7. (PMID: 9384604)
J Pediatr. 1997 Dec;131(6):922-5. (PMID: 9427902)
Pediatrics. 1998 Nov;102(5):E51. (PMID: 9794981)
المشرفين على المادة: 0 (Anticonvulsants)
0 (Antipyretics)
تواريخ الأحداث: Date Created: 20170223 Date Completed: 20170614 Latest Revision: 20220408
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6464693
DOI: 10.1002/14651858.CD003031.pub3
PMID: 28225210
قاعدة البيانات: MEDLINE
الوصف
تدمد:1469-493X
DOI:10.1002/14651858.CD003031.pub3